Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026

Same author

In Reply.

Archives of pathology & laboratory medicine·2026

Same author

Progress in Thymic Malignancy Care: The Imperative for Global Standards and Collaboration.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

Same author

Pulmonary venoocclusive disease/pulmonary capillary hemangiomatosis: Inadequacy of clinico-radiologic features in diagnosis.

Human pathology·2026

Same author

International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Same journal

An Update on Soft Tissue Tumors of the Paratesticular Region.

Advances in anatomic pathology·2026

Same journal

Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management.

Advances in anatomic pathology·2026

Same journal

Hereditary and Familial Tumor Syndromes: When to Think of Them? The Emerging Role of Pathologists as Sentinels of Genetic Cancer Predisposition.

Advances in anatomic pathology·2026

Same journal

From Familial Clustering to a Dedicated Classification: The Historical Recognition of Hereditary Tumor Syndromes in the WHO Classification of Tumors.

Advances in anatomic pathology·2026

Same journal

The Role of the Surgical Pathologist in the Recognition of Hereditary SDH-Deficient Tumor Syndromes.

Advances in anatomic pathology·2026

Same journal

DICER1 Syndrome and Tumor Pathology: An Updated Review for Diagnostic Practice.

Advances in anatomic pathology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Molecularly Defined Thoracic Neoplasms.

¹Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN.

Advances in Anatomic Pathology

|March 19, 2024

Summary

This summary is machine-generated.

Molecularly defined thoracic neoplasms like NUT carcinoma and SMARCA4-deficient undifferentiated tumors are increasingly recognized. Diagnosis is crucial for targeted therapies and clinical trials, improving patient management.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery

Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery

Published on: May 4, 2022

Related Experiment Videos

Last Updated: Jun 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery

Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery

Published on: May 4, 2022

Area of Science:

Thoracic oncology
Molecular pathology
Neoplasm classification

Background:

Molecular studies are enhancing the characterization and understanding of neoplasm pathogenesis.
Thoracic neoplasms increasingly recognized include NUT carcinoma, SMARCA4-deficient undifferentiated tumor (DUT), EWSR1::CREB1-fused pulmonary myxoid sarcoma, hyalinizing clear cell carcinoma, and SMARCB1-deficient neoplasms.
Availability of specific immunostains (NUT, BRG1, INI-1) and cytogenetic studies (EWSR1) aids in diagnosing these rare tumors.

Purpose of the Study:

To review current knowledge on the clinical, morphologic, immunophenotypic, and molecular features of specific rare thoracic neoplasms.
To highlight the importance of accurate diagnosis for patient management and treatment strategies.

Main Methods:

Review of clinical, morphologic, immunophenotypic, and molecular data.
Emphasis on diagnostic tools including immunostains and cytogenetics.
Literature review of identified neoplasms.

Main Results:

Molecularly defined thoracic neoplasms are becoming more identifiable.
Diagnostic markers like NUT, BRG1, and INI-1 immunostains, along with EWSR1 cytogenetics, are key for recognition.
Accurate diagnosis facilitates access to specialized clinical trials for certain neoplasms.

Conclusions:

Improved recognition of molecularly defined thoracic neoplasms is essential.
Diagnostic advancements enable better patient stratification and treatment selection.
Understanding these rare tumors is critical for advancing thoracic oncology care.